Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS110) in combination with nivolumab in the ongoing DURGA trial

Category Primary study
JournalJournal Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 0038b121e6fa2c31c6c79ac3987673007fe10abb
First added on: Jun 08, 2020